TELA Bio Inc. (TELA)
TELA trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/0001104659-26-034507-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TELA on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001561921 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $80.3M |
| Net income | -$38.8M |
| Operating income | -$33.8M |
| Net margin | -48.4% |
| Operating margin | -42.0% |
| Revenue growth | +15.8% |
| Cash | $50.8M |
| Total assets | $81.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Notes to Unaudited Interim Consolidated Financial Statements (Continued) These conditions and events raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued." | 10-Q 2026-11-10 |
| Cash and burn | $22.7M cash; operating cash flow -$8.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 45,188,230 (2026-11-05); 40,341,535 a year earlier; 24,488,803 three years earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-11-10 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-09-18 |
| Auditor | KPMG LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-04-21 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $4.2M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $19.0M | -$9.3M | -$8.7M | $22.7M | $56.3M | $78.2M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $19.3M | -$11.3M | -$9.4M | $30.4M | $56.1M | $79.9M | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $19.1M | -$12.3M | -$11.2M | $39.5M | $55.9M | $80.8M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $20.9M | -$9.0M | -$4.9M | $50.8M | $55.7M | $80.3M | 10-K 2026-03-25 |
| Q3 2025 2025-09-30 | $20.7M | -$8.6M | -$5.7M | $29.7M | $41.5M | $77.1M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $20.2M | -$9.9M | -$7.9M | $35.0M | $41.4M | $75.3M | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $18.5M | -$11.3M | -$9.7M | $42.8M | $41.3M | $71.2M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $17.6M | -$9.2M | -$7.5M | $52.7M | $41.1M | $69.3M | 10-K 2026-03-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-11-10 |
| Latest annual report | 10-K | 2026-03-25 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report FORM 8-K | 8-K | 2026-11-10 |
| Latest proxy | DEF 14A | 2026-09-14 |
Source: SEC EDGAR submissions feed, 551 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | 0.0% |
| 1 month | -23.0% |
| 3 months | +20.9% |
| Year to date | -30.5% |
| 1 year | -26.1% |
| From 52-week high | -41.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NEPH | Nephros Inc. | $3.00 | -1.64% | $32.6M |
| SRTS | Sensus Healthcare Inc. | $2.34 | +0.65% | $38.5M |
| XTNT | Xtant Medical Holdings Inc. | $0.2098 | -22.78% | $29.4M |
| MDAI | Spectral AI Inc. | $1.31 | +0.77% | $42.2M |
| NSPR | InspireMD Inc. | $0.6000 | -6.85% | $28.1M |
| MBOT | Microbot Medical Inc. | $0.6444 | -34.16% | $43.3M |
| ADGM | Adagio Medical Holdings Inc | $1.61 | -16.58% | $44.2M |
| PLRZ | Polyrizon Ltd. | $10.70 | -2.37% | $26.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier